The Safety and Accuracy of Drug Patch Testing in Delayed Hypersensitivity Reactions
Purpose of Review Adverse drug reactions are common in both the inpatient and outpatient settings and lead to limitations in future treatment options. Patch testing, used in conjunction with clinical history and the reaction phenotype, can help to improve identification of the culprit medication and evidence for its use is growing. Here we discuss a standardized approach to patch testing which can lead to accurate and reproducible results. Recent Findings Although patch testing may have low sensitivity, specificity is generally high with good utility depending on reaction phenotype and implicated medication. Patch testing has the highest sensitivity for acute generalized exanthematous pustulosis and drug reaction with eosinophilia and systemic symptoms and at the site of fixed drug eruptions. It has the lowest sensitivity in Stevens-Johnson/toxic epidermal necrolysis. Summary Patch testing, used in conjunction with clinical history, can help to improve identification of the culprit medication depending on reaction phenotype. Overall, it is safe to perform patch testing with rare risk of reactivation of primary reaction..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Current dermatology reports - 12(2023), 4 vom: 28. Sept., Seite 260-268 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saff, Rebecca R. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Adverse drug reaction |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s13671-023-00405-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054283876 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054283876 | ||
| 003 | DE-627 | ||
| 005 | 20240106064643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240106s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13671-023-00405-9 |2 doi | |
| 035 | |a (DE-627)SPR054283876 | ||
| 035 | |a (SPR)s13671-023-00405-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saff, Rebecca R. |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Safety and Accuracy of Drug Patch Testing in Delayed Hypersensitivity Reactions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose of Review Adverse drug reactions are common in both the inpatient and outpatient settings and lead to limitations in future treatment options. Patch testing, used in conjunction with clinical history and the reaction phenotype, can help to improve identification of the culprit medication and evidence for its use is growing. Here we discuss a standardized approach to patch testing which can lead to accurate and reproducible results. Recent Findings Although patch testing may have low sensitivity, specificity is generally high with good utility depending on reaction phenotype and implicated medication. Patch testing has the highest sensitivity for acute generalized exanthematous pustulosis and drug reaction with eosinophilia and systemic symptoms and at the site of fixed drug eruptions. It has the lowest sensitivity in Stevens-Johnson/toxic epidermal necrolysis. Summary Patch testing, used in conjunction with clinical history, can help to improve identification of the culprit medication depending on reaction phenotype. Overall, it is safe to perform patch testing with rare risk of reactivation of primary reaction. | ||
| 650 | 4 | |a Adverse drug reaction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug allergy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug hypersensitivity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Severe cutaneous adverse reaction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Skin testing |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Patch testing |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Waldron, Jamie L. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current dermatology reports |d New York, NY : Springer, 2012 |g 12(2023), 4 vom: 28. Sept., Seite 260-268 |w (DE-627)SPR032151217 |w (DE-600)2660493-0 |x 2162-4933 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:4 |g day:28 |g month:09 |g pages:260-268 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13671-023-00405-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 4 |b 28 |c 09 |h 260-268 | ||